TW200742580A - Methods for treating nephrolithiasis - Google Patents

Methods for treating nephrolithiasis

Info

Publication number
TW200742580A
TW200742580A TW095141385A TW95141385A TW200742580A TW 200742580 A TW200742580 A TW 200742580A TW 095141385 A TW095141385 A TW 095141385A TW 95141385 A TW95141385 A TW 95141385A TW 200742580 A TW200742580 A TW 200742580A
Authority
TW
Taiwan
Prior art keywords
methods
nephrolithiasis
treating
treating nephrolithiasis
administering
Prior art date
Application number
TW095141385A
Other languages
English (en)
Chinese (zh)
Inventor
Nancy Joseph-Ridge
Original Assignee
Tap Pharmaceutical Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Prod Inc filed Critical Tap Pharmaceutical Prod Inc
Publication of TW200742580A publication Critical patent/TW200742580A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
TW095141385A 2005-05-09 2006-11-08 Methods for treating nephrolithiasis TW200742580A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67898705P 2005-05-09 2005-05-09
US11/429,734 US8841333B2 (en) 2005-05-09 2006-05-08 Methods for treating nephrolithiasis
PCT/US2006/017663 WO2006121995A2 (en) 2005-05-09 2006-05-08 Methods for treating nephrolithiasis

Publications (1)

Publication Number Publication Date
TW200742580A true TW200742580A (en) 2007-11-16

Family

ID=37397189

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095141385A TW200742580A (en) 2005-05-09 2006-11-08 Methods for treating nephrolithiasis

Country Status (6)

Country Link
US (1) US8841333B2 (enExample)
EP (1) EP1883405A4 (enExample)
JP (2) JP2008545627A (enExample)
CA (1) CA2607953A1 (enExample)
TW (1) TW200742580A (enExample)
WO (1) WO2006121995A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1883405A4 (en) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US20070167454A1 (en) * 2005-08-03 2007-07-19 Christopher Lademacher Methods for treating hypertension
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
MX2009004984A (es) * 2006-11-13 2009-09-23 Takeda Pharmaceuticals North A Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
RU2371182C1 (ru) * 2008-02-11 2009-10-27 Петр Изевич Шустер Способ лечения и профилактики рецидивирования мочекаменной болезни у мужчин
BR112012032033A2 (pt) 2010-06-16 2017-10-31 Takeda Pharmaceuticals Usa Inc novas formas de dosagem de libertação modificada de inibidor de xantina oxidorredutase ou inibidores de xantina oxidase
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
KR20230119303A (ko) * 2022-02-07 2023-08-16 (주)인드림헬스케어 높은 혈중 요산 농도를 갖는 대상체의 만성 신장 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4296122A (en) * 1975-07-09 1981-10-20 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids
DE2707270A1 (de) 1977-02-19 1978-08-24 Hoechst Ag Pyrazolo-diazepine und verfahren zu ihrer herstellung
DE2707268A1 (de) 1977-02-19 1978-08-31 Hoechst Ag Indol-3-carbaldehyd-oxime und verfahren zu ihrer herstellung
DE2707269A1 (de) 1977-02-19 1978-08-24 Hoechst Ag Heterocyclische stickstoffverbindungen und verfahren zu ihrer herstellung
DE2727802A1 (de) 1977-06-21 1979-04-19 Hoechst Ag Sulfamoyl-arylketone und verfahren zu ihrer herstellung
JPS5936919B2 (ja) 1978-10-14 1984-09-06 日本新薬株式会社 インド−ル誘導体
DE3112116A1 (de) 1981-03-27 1982-11-04 Mundipharma GmbH, 6250 Limburg "arzneimittel"
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
DE3232922A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Sulfamoylbenzophenon-derivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
US4632930A (en) * 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
JPH0366669A (ja) * 1989-08-03 1991-03-22 Shionogi & Co Ltd 複素環式化合物
JP2725886B2 (ja) * 1990-11-30 1998-03-11 帝人株式会社 ２―アリールチアゾール誘導体及びその医薬組成物
WO1993004688A1 (en) 1991-09-09 1993-03-18 Warner-Lambert Company Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist
US5358961A (en) 1991-11-30 1994-10-25 Jin Ro Limited Pyrrolidine derivatives
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07242694A (ja) 1994-02-28 1995-09-19 Yamasa Shoyu Co Ltd トリアゾロプリンヌクレオシド誘導体及び該誘導体を製造するのに有用な合成中間体
US6037344A (en) * 1994-08-17 2000-03-14 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US5514681A (en) * 1994-08-17 1996-05-07 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US5770601A (en) * 1994-08-17 1998-06-23 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
AUPM835394A0 (en) * 1994-09-23 1994-10-13 King, Michael G. Dr. Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need
EP0811624A1 (en) 1995-02-21 1997-12-10 Yamasa Corporation Purine compounds and xanthine oxidase inhibitors
US6084147A (en) 1995-03-17 2000-07-04 Studsvik, Inc. Pyrolytic decomposition of organic wastes
CA2190993C (en) 1995-04-07 2004-06-01 Mikio Ota Protective agent for organ or tissue
ID21775A (id) * 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
US5965625A (en) * 1997-03-21 1999-10-12 King; Michael Glenn Compositions and methods for the control of smoking
EP1044002A4 (en) * 1997-11-07 2003-05-02 Univ Johns Hopkins METHODS FOR THE TREATMENT OF HEART CONTRACTILITY
JPH11140086A (ja) 1997-11-07 1999-05-25 Yamasa Shoyu Co Ltd ４−置換−１Ｈ−６−オキソピラゾロ［３，４−ｄ］ピリミジン化合物及びキサンチンオキシダーゼ阻害剤
CZ298170B6 (cs) * 1998-06-19 2007-07-11 Teijin Limited Polymorfní a amorfní modifikace 2-(3-kyan-4-isobutoxyfenyl)-4-methyl-5-thiazolkarboxylové kyseliny a zpusob jejich prípravy
HU228916B1 (en) 1998-08-06 2013-06-28 Mountain View Pharmaceuticals Polyethylen-glycol/carbamate oxydase conjugates and pharmaceutical compositions containing thereof
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
US6281222B1 (en) * 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
US7799794B2 (en) * 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
ITMI20010206A1 (it) 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
EP1416942B1 (en) * 2001-04-18 2007-12-12 Genzyme Corporation Amine polymers for treating gout and binding uric acid
EP1435951B1 (en) 2001-10-12 2006-01-18 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity
RU2293733C2 (ru) * 2002-01-28 2007-02-20 Фуджи Якухин Ко., Лтд. Новые 1,2,4-триазольные соединения, способы их получения и содержащие их лекарственные средства
US20060040945A1 (en) * 2002-05-17 2006-02-23 Merckle Gmbh Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
US7078423B2 (en) 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US20040131676A1 (en) * 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
WO2006028342A1 (en) 2004-09-06 2006-03-16 Biosynergen, Inc. A novel xanthine oxidase inhibitor and a pharmaceutical composition containing the same
EP1819334A1 (en) 2004-11-19 2007-08-22 Shiva Biomedical, LLC Methods of treating erythropoietin-resistance
EP1883405A4 (en) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US20070167454A1 (en) * 2005-08-03 2007-07-19 Christopher Lademacher Methods for treating hypertension
US20090124623A1 (en) 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
MX2009004984A (es) * 2006-11-13 2009-09-23 Takeda Pharmaceuticals North A Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
AU2008206231A1 (en) 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
MX2007011927A (es) 2007-09-26 2009-03-26 World Trade Imp Export Wtie Ag Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas.
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CA2812034C (en) * 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat

Also Published As

Publication number Publication date
EP1883405A4 (en) 2010-01-27
JP2013151518A (ja) 2013-08-08
US8841333B2 (en) 2014-09-23
WO2006121995A3 (en) 2007-03-22
US20060252808A1 (en) 2006-11-09
EP1883405A2 (en) 2008-02-06
JP2008545627A (ja) 2008-12-18
WO2006121995A2 (en) 2006-11-16
CA2607953A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
MX2009004984A (es) Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
DE60329001D1 (en) 8-hydroxychinolinderivate
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
WO2007085019A3 (en) Methods of treating or preventing sinusitis with oxidative reductive potential water solution
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
WO2006113942A3 (en) Method of inhibiting cathepsin activity
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
ZA200706530B (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
TW200806299A (en) Treatment of pain
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
MX2008012479A (es) Tratamiento de enfermedades neurodegenerativas.
MX2009005649A (es) Tratamiento para mieloma multiple.
WO2007019153A3 (en) Methods for treating hypertension
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
PL1900362T3 (pl) Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
TW200639159A (en) Treatment of pain
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
TW200742580A (en) Methods for treating nephrolithiasis
TW200700071A (en) Novel use
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
WO2006071456A3 (en) Inhibition of hsp27 phosphorylation for treatment of blistering disorders